Skip to main content
OpenTrials

Clinical trial condition

Blasts Under 5 Percent of Bone Marrow Nucleated Cells

Explore clinical trials studying Blasts Under 5 Percent of Bone Marrow Nucleated Cells. Study availability and eligibility vary by location and protocol.

3 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Blasts Under 5 Percent of Bone Marrow Nucleated Cells trial results

Recruiting

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

NCT03779854

Conditions
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, +54 more
Locations
  • Children's Hospital of Los Angeles Los Angeles, California, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
  • Children's Healthcare of Atlanta Atlanta, Georgia, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
View Trial Details
Completed

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

NCT00796068

Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, +25 more
Locations
  • University of Colorado Hospital Aurora, Colorado, United States
  • Oregon Health and Science University Portland, Oregon, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Completed

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

NCT01527045

Conditions
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Blood Protein Disorders, +57 more
Locations
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details

Related conditions